Publication: Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma
Date
Date
Date
Citations
Bhave, P., Ahmed, T., Lo, S. N., Shoushtari, A., Zaremba, A., Versluis, J. M., Mangana, J., Weichenthal, M., Si, L., Lesimple, T., Robert, C., Trojanello, C., Wicky, A., Heywood, R., Tran, L., Batty, K., Dimitriou, F., Stansfeld, A., Allayous, C., … et al. (2022). Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. Journal for ImmunoTherapy of Cancer, 10, e004668. https://doi.org/10.1136/jitc-2022-004668
Abstract
Abstract
Abstract
BackgroundAcral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1) agents nivolumab and pembrolizumab. There is therefore an absence of prospective clinical trial evidence regarding the efficacy of checkpoint inhibitors (CPIs) in this population. Acral melanoma has lower tumor mutation burden (TMB) than other cutaneous sites, and primary site is associated
Additional indexing
Creators (Authors)
Volume
Volume
Volume
Number
Number
Number
Page range/Item number
Page range/Item number
Page range/Item number
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Keywords
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Free Access at
Free Access at
Free Access at
Publisher DOI
Citations
Bhave, P., Ahmed, T., Lo, S. N., Shoushtari, A., Zaremba, A., Versluis, J. M., Mangana, J., Weichenthal, M., Si, L., Lesimple, T., Robert, C., Trojanello, C., Wicky, A., Heywood, R., Tran, L., Batty, K., Dimitriou, F., Stansfeld, A., Allayous, C., … et al. (2022). Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma. Journal for ImmunoTherapy of Cancer, 10, e004668. https://doi.org/10.1136/jitc-2022-004668